Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00986830
Other study ID # 1630-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2009
Est. completion date September 2012

Study information

Verified date October 2020
Source Entellus Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, nonrandomized trial to evaluate postoperative healthcare resource utilization after maxillary balloon antrostomy using FinESS Sinus Treatment in the physician's office.


Description:

A prospective, nonrandomized trial to evaluate postoperative healthcare resource utilization after maxillary balloon antrostomy using FinESS Sinus Treatment in the physician's office. Also to demonstrate the long-term durability of FinESS Sinus Treatment performed in an office setting.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Male or female subjects - Diagnosis of rhinosinusitis (CT radiographic evidence and medical evaluation) - Willing to comply with protocol requirements - Able to provide consent Exclusion Criteria: - Hemophilia - Cystic fibrosis - Ciliary dysfunction - Severe septal deviation causing obstruction of the ostiomeatal unit - Pregnant females

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FinESS Sinus Treatment


Locations

Country Name City State
United States Austin Ear, Nose and Throat Austin Texas
United States Texas Sinus Center Boerne Texas
United States The Snoring Center Dallas Texas
United States South Denver ENT and Allergy Denver Colorado
United States NorthShore University Evanston Illinois
United States Central California ENT Fresno California
United States Holston Medical Center Kingsport Tennessee
United States Advanced ENT and Allergy Louisville Kentucky
United States Coastal Ear, Nose and Throat Associates New Bern North Carolina
United States Advanced Otolaryngology PC Richmond Virginia
United States St. Cloud Ear, Nose and Throat Saint Cloud Minnesota
United States Midwest Ear, Nose and Throat Sioux Falls South Dakota
United States ENT and Allergy Associates Trumbull Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Entellus Medical, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Levine SB, Truitt T, Schwartz M, Atkins J. In-office stand-alone balloon dilation of maxillary sinus ostia and ethmoid infundibula in adults with chronic or recurrent acute rhinosinusitis: a prospective, multi-institutional study with-1-year follow-up. An — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sino-Nasal Outcomes Test The 20-item Sino-Nasal Outcomes Test (SNOT-20) is a validated, disease-specific patient-reported instrument designed to indicate the severity of rhinosinusitis symptoms. The SNOT-20 evaluates 20 symptoms on a scale from 0 ("no problem") to 5 ("problem as bad as it can be"). The overall SNOT-20 score is the average of the 20 symptoms scores providing a range from 0 to 5 with higher scores indicating worse symptoms. The minimal clinically important difference (MCID) has been determined to be a reduction of 0.8 or more in the overall SNOT-20 score. Baseline and 12 months post procedure
Secondary Rhinosinusitis Symptom Inventory (RSI) Nasal Symptoms Domain The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 1 of the questionnaire scores symptoms related to chronic rhinosinusitis on a 6-point scale with "0" indicating no symptoms and "5" indicating very severe symptoms. There are 4 symptoms domains: nasal, facial, oropharyngeal, and systemic. RSI domain scores are calculated by summing the score of the specific domain question, dividing by the number of domain questions, and multiplying by 20 to obtain a standardized score. Scores can range from 0 to 100 with higher scores indicating worse symptoms. Baseline and 12 months post procedure
Secondary Rhinosinusitis Symptom Inventory (RSI) Facial Symptoms Domain The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 1 of the questionnaire scores symptoms related to chronic rhinosinusitis on a 6-point scale with "0" indicating no symptoms and "5" indicating very severe symptoms. There are 4 symptoms domains: nasal, facial, oropharyngeal, and systemic. RSI domain scores are calculated by summing the score of the specific domain question, dividing by the number of domain questions, and multiplying by 20 to obtain a standardized score. Scores can range from 0 to 100 with higher scores indicating worse symptoms. Baseline and 12 months post procedure
Secondary Rhinosinusitis Symptom Inventory (RSI) Oropharyngeal Symptoms Domain The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 1 of the questionnaire scores symptoms related to chronic rhinosinusitis on a 6-point scale with "0" indicating no symptoms and "5" indicating very severe symptoms. There are 4 symptoms domains: nasal, facial, oropharyngeal, and systemic. RSI domain scores are calculated by summing the score of the specific domain question, dividing by the number of domain questions, and multiplying by 20 to obtain a standardized score. Scores can range from 0 to 100 with higher scores indicating worse symptoms. Baseline and 12 months post procedure
Secondary Rhinosinusitis Symptom Inventory (RSI) Systemic Symptoms Domain The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 1 of the questionnaire scores symptoms related to chronic rhinosinusitis on a 6-point scale with "0" indicating no symptoms and "5" indicating very severe symptoms. There are 4 symptoms domains: nasal, facial, oropharyngeal, and systemic. RSI domain scores are calculated by summing the score of the specific domain question, dividing by the number of domain questions, and multiplying by 20 to obtain a standardized score. Scores can range from 0 to 100 with higher scores indicating worse symptoms. Baseline and 12 months post procedure
Secondary Number of Participants Using Nasal Steroids The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 2 of the questionnaire records medication usage (nasal steroid sprays, anti-histamines, and antibiotics) over the past 12 months. Baseline and 12 months post procedure
Secondary Number of Participants Using Antihistamines The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 2 of the questionnaire records medication usage (nasal steroid sprays, anti-histamines, and antibiotics) over the past 12 months. Baseline and 12 months post procedure
Secondary Number of Participants Using Antibiotics The Rhinosinusitis Symptom Inventory (RSI) is a self-administered quality of life questionnaire. Section 2 of the questionnaire records medication usage (nasal steroid sprays, anti-histamines, and antibiotics) over the past 12 months. Baseline and 12 months post procedure
Secondary Number of Participants With Device and/or Procedure-related Adverse Events Number of participants with 1 or more adverse events considered possibly or definitely related to the FinESS device and/or balloon dilation procedure. Baseline through 12 months post procedure
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02636790 - Early Versus Late Surgical Wait Times Early Phase 1
Completed NCT02712502 - Levofloxacin in Bacterial Rhinosinussitis N/A
Completed NCT00534079 - Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Phase 3
Completed NCT05442606 - Physiotherapy Protocol in Treating Chronic Rhinosinusitis N/A
Completed NCT01955980 - Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis Phase 1/Phase 2
Completed NCT04123405 - Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis Phase 3
Completed NCT00797004 - Olfactory Dysfunction of Rhinosinusitis N/A
Recruiting NCT05494346 - Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction N/A
Not yet recruiting NCT05836935 - Role of Imaging in Complications of Sinusitis N/A
Withdrawn NCT02097576 - Manuka Honey Nasal Rinse Study N/A
Completed NCT01132781 - Theophylline in Rhinitis Phase 2
Recruiting NCT00948519 - Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents N/A
Completed NCT00554190 - Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel Phase 4
Recruiting NCT03729258 - Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. Phase 3
Withdrawn NCT03729310 - Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis Early Phase 1
Recruiting NCT01296919 - The Clinical Significance of the Uncinate Process Histopathology in Chronic Rhinosinusitis N/A
Completed NCT01086839 - Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis N/A
Completed NCT00849953 - FinESS Registry Study N/A
Withdrawn NCT00669799 - Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study N/A
Completed NCT03229551 - Xylitol for Chronic Sinusitis Phase 2/Phase 3